Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials

BACKGROUND: Cilostazol overcomes high on-treatment platelet reactivity (HTPR) and reduces adverse cardiovascular (CV) outcomes after percutaneous coronary intervention (PCI). However, the role for triple antiplatelet therapy (TAPT) with cilostazol in addition to aspirin and clopidogrel after PCI is...

Descripción completa

Detalles Bibliográficos
Autores principales: Bangalore, Sripal, Singh, Amita, Toklu, Bora, DiNicolantonio, James J, Croce, Kevin, Feit, Frederick, Bhatt, Deepak L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Coronary Artery Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189225/
https://www.ncbi.nlm.nih.gov/pubmed/25332804
http://dx.doi.org/10.1136/openhrt-2014-000068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189225/
https://www.ncbi.nlm.nih.gov/pubmed/25332804
http://dx.doi.org/10.1136/openhrt-2014-000068

Ejemplares similares